Thrombosis Update最新文献

筛选
英文 中文
Long-term survival and cerebrovascular events after carotid artery stenting in patients with chronic kidney disease
Thrombosis Update Pub Date : 2024-12-01 DOI: 10.1016/j.tru.2024.100193
Qiaoming Jiang , Jiangkai Yu , Yutao Zhao , Bichao Wang , Xixiang Gao , Yingchun Xiao
{"title":"Long-term survival and cerebrovascular events after carotid artery stenting in patients with chronic kidney disease","authors":"Qiaoming Jiang ,&nbsp;Jiangkai Yu ,&nbsp;Yutao Zhao ,&nbsp;Bichao Wang ,&nbsp;Xixiang Gao ,&nbsp;Yingchun Xiao","doi":"10.1016/j.tru.2024.100193","DOIUrl":"10.1016/j.tru.2024.100193","url":null,"abstract":"<div><h3>Objective</h3><div>Chronic kidney disease (CKD) is associated with cerebrovascular diseases (CVDs) due to chronic systemic inflammation. This study aimed to estimate perioperative and long-term outcomes in Chinese patients undergoing carotid artery stenting (CAS) who had different stages of CKD.</div></div><div><h3>Method</h3><div>This retrospective study enrolled 888 patients undergoing CAS for carotid artery stenosis. Patients were classified into normal, mild, moderate, and severe CKD and dialysis groups based on their renal function. The primary endpoint was long-term survival from a major adverse event (MAE), which was predefined as the development of a stroke, myocardial infarction (MI), or death during a 10-year long-term follow-up.</div></div><div><h3>Results</h3><div>Perioperative rates for MAE were 1.5 %, 1.8 %, 3.0 %, 10.3 %, and 9.1 % for the five categories (<em>p</em> &lt; 0.001). There was no death within the perioperative 30 days. The estimated 5-year death-free survival rates decreased with worsening renal function (92.2 % vs. 82.7 % vs. 76.9 % vs. 61.4 % vs. 58.6 %, <em>p</em> &lt; 0.001). The long-term MAE-free survival was 94.7 % vs. 91.0 % vs. 80.2 % vs. 63.7 % vs. 52.2 % for the groups, with the differences being significant between normal to moderate CKD and severe CKD and hemodialysis-dependent cases. Cox regression analysis revealed that dialysis (HR = 3.216 (95%CI: 1.662, 6.223), <em>p</em> = 0.001), severe CKD (HR = 4.592 (95%CI: 2.348, 8.982), <em>p</em> &lt; 0.001), hypertension (HR = 1.977 (95%CI: 1.292, 3.024), <em>p</em> = 0.002), coronary artery disease (HR = 1.509 (95%CI: 1.037, 2.196), <em>p</em> = 0.032) and diabetes mellitus (HR = 2.459 (95%CI: 1.482, 4.079), <em>p</em> &lt; 0.001) were predictors of long-term MAE after CAS.</div></div><div><h3>Conclusion</h3><div>Risk of perioperative and long-term MAE increased with CKD severity. Patients with normal to moderate CKD benefited from MAE-free survival after CAS. However, preventive CAS appeared to be inappropriate in severe CKD or hemodialysis cases with asymptomatic carotid stenosis, particularly in those with a number of comorbidities.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"17 ","pages":"Article 100193"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving management of catheter related thrombosis (CRT) in cancer patients by incorporating real world data. The value of cancer VTE registries
Thrombosis Update Pub Date : 2024-12-01 DOI: 10.1016/j.tru.2024.100195
Dr Emmanouil S. Papadakis MD, MSc, Dr Lucy A. Norris PhD
{"title":"Improving management of catheter related thrombosis (CRT) in cancer patients by incorporating real world data. The value of cancer VTE registries","authors":"Dr Emmanouil S. Papadakis MD, MSc,&nbsp;Dr Lucy A. Norris PhD","doi":"10.1016/j.tru.2024.100195","DOIUrl":"10.1016/j.tru.2024.100195","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"17 ","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study 组织因子 (F3) 基因变异与中老年人血栓风险:基于人群的队列研究
Thrombosis Update Pub Date : 2024-09-28 DOI: 10.1016/j.tru.2024.100190
Eric Manderstedt , Christina Lind-Halldén , Christer Halldén , Johan Elf , Peter J. Svensson , Gunnar Engström , Olle Melander , Aris Baras , Luca A. Lotta , Bengt Zöller , for the Regeneron Genetics Center
{"title":"Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study","authors":"Eric Manderstedt ,&nbsp;Christina Lind-Halldén ,&nbsp;Christer Halldén ,&nbsp;Johan Elf ,&nbsp;Peter J. Svensson ,&nbsp;Gunnar Engström ,&nbsp;Olle Melander ,&nbsp;Aris Baras ,&nbsp;Luca A. Lotta ,&nbsp;Bengt Zöller ,&nbsp;for the Regeneron Genetics Center","doi":"10.1016/j.tru.2024.100190","DOIUrl":"10.1016/j.tru.2024.100190","url":null,"abstract":"<div><h3>Background</h3><div>Tissue factor (TF), encoded by the <em>F3</em> gene, is the main initiator of blood coagulation. The molecular epidemiology of the <em>F3</em> gene and the relation to venous thromboembolism (VTE) remains to be determined.</div></div><div><h3>Objectives</h3><div>The aim was to determine the molecular epidemiology and the importance of <em>F3</em> variants for incident VTE by analysis of the population-based MDC study (Malmö Diet and Cancer), consisting of unselected middle-aged and older individuals.</div></div><div><h3>Methods</h3><div>The exons of <em>F3</em> were analyzed in a total of 28,794 individuals from the MDC cohort, and of these, 2584 (9 %) were affected by VTE during follow‐up (1991–2018). Qualifying variants used in gene-collapsing analysis were defined as loss-of-function or non-benign (PolyPhen-2) missense variants with minor allele frequency less than 0.1 %.</div></div><div><h3>Results</h3><div>Exon sequencing of the <em>F3</em> gene identified 61 different variants, 3′ UTR variants (n = 5), 5′ UTR variants (n = 9) synonymous (n = 10), in frame insertion (n = 1), splice region variants (n = 2), missense (n = 33) or loss-of-function variants (n = 1). No associations between common <em>F3</em> gene variants and incident VTE were found. Seventeen rare variants were classified as qualifying and included in collapsing analysis (16 non-benign missense and 1 loss-of-function variants). The prevalence of <em>F3</em> qualifying variants was 0.14 %. Seven individuals with <em>F3</em> qualifying variants had VTE, while 34 individuals had no VTE. The adjusted VTE model was significant (hazard ratio = 2.1 [95 % confidence interval, 1.02–4.48], <em>P-value</em> = 0.045).</div></div><div><h3>Conclusions</h3><div>Qualifying <em>F3</em> gene variants are very rare, indicating a constrained gene. Rare but not common variation in the <em>F3</em> gene may be involved in VTE.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"17 ","pages":"Article 100190"},"PeriodicalIF":0.0,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) 癌症患者导管相关血栓形成:来自 SEOM 血栓形成和瘤变登记处(TESEO)的数据
Thrombosis Update Pub Date : 2024-09-25 DOI: 10.1016/j.tru.2024.100191
Francisco José Pelegrín Mateo , Teresa Quintanar Verdúguez , Dialina Brilhante , Asia Ferrández Arias , Alejandra Romano Cardozo , Eva Martínez de Castro , José Muñoz Langa , Elena Brozos Vázquez , María Vallamayor Delgado , Berta Obispo Portero , Enrique Gallardo , José Rubio Pérez , Isaura Fernández Pérez , Ignacio García Escobar , Silvia García Adrián , José Antonio Santiago Crespo , Lola Rodríguez-Nogueira , Gretel Benítez López , Paula Jimenez-Fonseca , Andrés Muñoz Martín
{"title":"Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)","authors":"Francisco José Pelegrín Mateo ,&nbsp;Teresa Quintanar Verdúguez ,&nbsp;Dialina Brilhante ,&nbsp;Asia Ferrández Arias ,&nbsp;Alejandra Romano Cardozo ,&nbsp;Eva Martínez de Castro ,&nbsp;José Muñoz Langa ,&nbsp;Elena Brozos Vázquez ,&nbsp;María Vallamayor Delgado ,&nbsp;Berta Obispo Portero ,&nbsp;Enrique Gallardo ,&nbsp;José Rubio Pérez ,&nbsp;Isaura Fernández Pérez ,&nbsp;Ignacio García Escobar ,&nbsp;Silvia García Adrián ,&nbsp;José Antonio Santiago Crespo ,&nbsp;Lola Rodríguez-Nogueira ,&nbsp;Gretel Benítez López ,&nbsp;Paula Jimenez-Fonseca ,&nbsp;Andrés Muñoz Martín","doi":"10.1016/j.tru.2024.100191","DOIUrl":"10.1016/j.tru.2024.100191","url":null,"abstract":"<div><h3>Background</h3><div>Catheter related thrombosis (CRT) is the most frequent non-infectious complication associated with central venous access devices (CVAD), with a reported incidence between 13 % and 66 % in symptomatic and asymptomatic patients, respectively, with several factors influencing its development.</div></div><div><h3>Methods</h3><div>CRT events recorded in TESEO, an international, multicentric, and prospective cancer-associated thrombosis registry were assessed. Descriptive analyses were conducted.</div></div><div><h3>Results</h3><div>Between July 2018 and December 2023, 2,567 patients were included in TESEO. Of these, 245 patients developed CRT and were included in this analysis. Mean age was 60.5 years (SD 12.3). Peripherally inserted central catheters (PICC) were present in 42.1%, totally implanted ports (PORT) in 40.9% while 17% had missing data. The most common reported comorbidities were arterial hypertension (28.6%) and dyslipidemia (28.2%). Other thromboembolism associated risk factors were present in ≤10% of patients.</div><div>Venous thromboembolism (VTE) related symptoms occurred in 70.2% of cases at presentation. Pulmonary embolism (PE) was present in 6.5%, being clinically suspected in 56.2% of cases. The diagnosis was mainly unilateral (81.3%) and 50% were central. Arterial and venous rethrombosis was present in 0.8% and 4.9% of cases respectively. Minor bleeding episodes occurred in 2.5% of cases, while major/clinically relevant episodes were present in 3.6%.</div></div><div><h3>Conclusions</h3><div>Usual VTE associated risk factors were infrequent in the TESEO registry population. CRT was symptomatic in most cases, with reduced complication rates after treatment.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"17 ","pages":"Article 100191"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing qLabs® FIB 的可用性研究:功能性纤维蛋白原检测的新型床旁系统
Thrombosis Update Pub Date : 2024-09-25 DOI: 10.1016/j.tru.2024.100192
Maxence Hureau , Anne-Sophie Bouthors , Lucie Deroo , Anne-Sophie Baptiste , Agnès Le Gouez , Mathias Rossignol , Frederic J. Mercier , Agnès Rigouzzo
{"title":"Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing","authors":"Maxence Hureau ,&nbsp;Anne-Sophie Bouthors ,&nbsp;Lucie Deroo ,&nbsp;Anne-Sophie Baptiste ,&nbsp;Agnès Le Gouez ,&nbsp;Mathias Rossignol ,&nbsp;Frederic J. Mercier ,&nbsp;Agnès Rigouzzo","doi":"10.1016/j.tru.2024.100192","DOIUrl":"10.1016/j.tru.2024.100192","url":null,"abstract":"<div><h3>Background</h3><div>Identification of hypofibrinogenemia is particularly important in obstetrics since this predicts progression to severe Post-Partum Haemorrhage (PPH).</div></div><div><h3>Objectives</h3><div>To evaluate the usability of qLabs® FIB at the bedside of patients with PPH.</div></div><div><h3>Methods</h3><div>The qLabs® FIB test was performed using a drop of whole blood from a citrated laboratory tube sampled from each parturient with PPH &gt;1 L by a trained user. A usability survey was completed by each clinician performing the test.</div></div><div><h3>Results</h3><div>During the evaluation, 101 qLabs® FIB tests were performed. One hundred completed surveys and 58 free comments were collected. Satisfaction was achieved in 84 % of tests. Usability in emergency setting, timeliness of results, and the results display were considered positive. The qLabs® FIB results were obtained in &lt;3 min for concentrations below 3 g/L whilst the median time to paired laboratory results was 60 (20–120) minutes. The lower a patient's fibrinogen level, the faster the qLabs® FIB result.</div></div><div><h3>Conclusion</h3><div>The usability study was the first step in the validation process of the qLabs® FIB point of care device in obstetric settings.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"17 ","pages":"Article 100192"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nitrous oxide and VTE – no laughing matter 一氧化二氮和 VTE--不是笑料
Thrombosis Update Pub Date : 2024-09-01 DOI: 10.1016/j.tru.2024.100188
Lucy A. Norris, Emmanouil S. Papadakis
{"title":"Nitrous oxide and VTE – no laughing matter","authors":"Lucy A. Norris,&nbsp;Emmanouil S. Papadakis","doi":"10.1016/j.tru.2024.100188","DOIUrl":"10.1016/j.tru.2024.100188","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"16 ","pages":"Article 100188"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000300/pdfft?md5=cca7db39af55ba8c3355b4e96dc70579&pid=1-s2.0-S2666572724000300-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting 在门诊环境中实施癌症相关血栓预防的实用模式
Thrombosis Update Pub Date : 2024-08-13 DOI: 10.1016/j.tru.2024.100187
João Gramaça , Ana Robalo Lopes, Marta Ganhão, Joana Gonçalves, Rita Gameiro, Isabel Fernandes, Adriano Baptista, Luísa Barbosa, Idília Pina
{"title":"Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting","authors":"João Gramaça ,&nbsp;Ana Robalo Lopes,&nbsp;Marta Ganhão,&nbsp;Joana Gonçalves,&nbsp;Rita Gameiro,&nbsp;Isabel Fernandes,&nbsp;Adriano Baptista,&nbsp;Luísa Barbosa,&nbsp;Idília Pina","doi":"10.1016/j.tru.2024.100187","DOIUrl":"10.1016/j.tru.2024.100187","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"16 ","pages":"Article 100187"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000294/pdfft?md5=8ceba687e678dd8c5260c022af9b9069&pid=1-s2.0-S2666572724000294-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies 造血干细胞移植和其他细胞疗法后的血栓并发症
Thrombosis Update Pub Date : 2024-08-07 DOI: 10.1016/j.tru.2024.100186
Paschalis Evangelidis , Eleni Gavriilaki , Dimitrios A. Tsakiris
{"title":"Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies","authors":"Paschalis Evangelidis ,&nbsp;Eleni Gavriilaki ,&nbsp;Dimitrios A. Tsakiris","doi":"10.1016/j.tru.2024.100186","DOIUrl":"10.1016/j.tru.2024.100186","url":null,"abstract":"<div><p>Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) immunotherapy are widely used for the management of hematological malignancies. HSCT can be complicated by endothelial injury syndromes, such as HSCT-thrombotic microangiopathy (HSCT-TMA) and sinusoidal obstructive syndrome/veno-occlusive disease (SOS/VOD), which are life-threatening. Moreover, venous thromboembolic events (VTEs) are common in HSCT recipients due to endothelial injury, use of central venous catheters, prolonged hospitalization, and the development of a procoagulant state. VTEs have also been reported post-CAR-T infusion. The management of thrombotic events in these patients is challenging, due to the high risk of bleeding that is present. CAR-T immunotherapy might be followed by toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associated neuro-toxicity syndrome (ICANS). Endothelial dysfunction is implicated in the pathogenesis of these syndromes. Early recognition and management of the above complications are crucial for better patient outcomes.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"16 ","pages":"Article 100186"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000282/pdfft?md5=81a6ec543fa848b1f54eee965017eeb7&pid=1-s2.0-S2666572724000282-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review 用 Xa 因子抑制剂治疗肝素诱发的血小板减少症:系统回顾
Thrombosis Update Pub Date : 2024-07-24 DOI: 10.1016/j.tru.2024.100185
Colton Jones , Abiodun Idowu , Elvis Obomanu , Raymond Smith , Karecia Byfield , Avinash Ramkissoon , Kevin Bryan Lo , Ryan Mayo
{"title":"Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review","authors":"Colton Jones ,&nbsp;Abiodun Idowu ,&nbsp;Elvis Obomanu ,&nbsp;Raymond Smith ,&nbsp;Karecia Byfield ,&nbsp;Avinash Ramkissoon ,&nbsp;Kevin Bryan Lo ,&nbsp;Ryan Mayo","doi":"10.1016/j.tru.2024.100185","DOIUrl":"10.1016/j.tru.2024.100185","url":null,"abstract":"<div><p>Heparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality. The mainstay of treatment for HIT involves discontinuing all heparin products and administering non-heparin anticoagulants. Since the publication of the American Society of Hematology (ASH) guidelines in 2018, factor Xa inhibitors have become an attractive alternative. We systematically reviewed the literature to determine the efficacy and safety of factor Xa inhibitors in managing HIT. We included any case series, retrospective, or prospective study that evaluated the efficacy of factor Xa inhibitors. We searched PubMed, Ovid, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar from inception to September 2023. Three reviewers independently reviewed titles, abstracts, and full-text articles to determine eligibility using prespecified inclusion and exclusion criteria. Disagreements were resolved by discussion and consensus. Nine hundred sixty-four articles were screened against title and abstract, and 75 studies were selected for full-text review. Fifteen studies eventually met the inclusion criteria. Two hundred eighty-five patients across 15 studies were treated with factor Xa inhibitor. Across all study arms combined, HIT thrombosis-associated mortality was 0 % (n = 0), recurrent thrombosis was 4.56 % (n = 13), and major bleeding was 2.80 % (n = 8). Factor Xa inhibitors showed positive outcomes in HIT in terms of both safety and efficacy. Major limitation of this review is that the studies included are primarily retrospective and, thus, are subject to inherent limitations of observational study design. More randomized controlled trials (RCT) or prospective studies examining non-inferiority or superiority of transitioning to direct oral anticoagulant (DOAC) vs primary treatment with DOAC are needed.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"16 ","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000270/pdfft?md5=237ceb7c77231c44b9e5334492078af2&pid=1-s2.0-S2666572724000270-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141838893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the prevalence of nitrous oxide usage in patients aged 35 years or under presenting with unprovoked VTE between 2021-2023 评估 2021-2023 年间 35 岁及以下无诱因 VTE 患者使用一氧化二氮的流行率。
Thrombosis Update Pub Date : 2024-07-23 DOI: 10.1016/j.tru.2024.100184
Christine Joerres , Marta Patyjewicz , Melisa Cetin, Tadbir Bariana, Barbara Onen, Luke Hone, Jonathan Green, Deepa Tambe, Philip Dalby, Amy Keller, Alastair Noyce
{"title":"Assessing the prevalence of nitrous oxide usage in patients aged 35 years or under presenting with unprovoked VTE between 2021-2023","authors":"Christine Joerres ,&nbsp;Marta Patyjewicz ,&nbsp;Melisa Cetin,&nbsp;Tadbir Bariana,&nbsp;Barbara Onen,&nbsp;Luke Hone,&nbsp;Jonathan Green,&nbsp;Deepa Tambe,&nbsp;Philip Dalby,&nbsp;Amy Keller,&nbsp;Alastair Noyce","doi":"10.1016/j.tru.2024.100184","DOIUrl":"10.1016/j.tru.2024.100184","url":null,"abstract":"<div><h3>Background</h3><p>Nitrous oxide (N<sub>2</sub>O), often known as \"laughing gas,\" ranks as a widely used recreational drug among young people in the UK, with 3.9 % of young adults aged 16–24 reporting its use in 2021–2022. Besides its known neurological risks, there is emerging evidence linking N<sub>2</sub>O misuse to serious haematological issues, including arterial and venous thrombosis.</p></div><div><h3>Aims/objectives</h3><p>The project aimed to elucidate the prevalence of N<sub>2</sub>O usage in young adults (18–35 years) with unprovoked venous thromboembolism (VTE) between January 2021 and July 2023.</p></div><div><h3>Method</h3><p>Patient records from three East London emergency departments (ED), coded with a SNOMED code for VTE upon ED discharge between January 2021 and June 2023, were compiled using Qliksense. The data extracted from electronic patient records (EPR) encompassed demographics, confirmed cases of VTE at discharge, and history of N<sub>2</sub>O usage. Criteria for exclusion included age restrictions, established provoking factors for VTE, and unconfirmed reports of N<sub>2</sub>O use.</p></div><div><h3>Results</h3><p>We found 26 patients, out of which 8 patients (31 %) reported N<sub>2</sub>O use. Among these, a majority of 7 patients (88 %) reported regular N<sub>2</sub>O at the time of admission for VTE. Furthermore, 6 patients (75 %) reported regular N<sub>2</sub>O use for at least 12 months. The quantity of N<sub>2</sub>O usage varied widely, ranging from 7 to 210 (mean = 61.9, ∼495g) small canisters per week with each canister containing 8 g of N<sub>2</sub>O. The duration of N<sub>2</sub>O use varied significantly ranging from 7 to 59 months (mean = 29.25). This group of young adults (18–35; mean = 25) was 88 % male and 12 % female. The ethnic distribution among the cohort was 62 % Asian or Asian British, 25 % Black or Black British, and 12 % White. Stratified by the index of multiple deprivation 25 % were in quintile 1–2, 50 % were 3–4, 12 % were 5–6, and 12 % were in 7–8 range (0 % 9–10).</p></div><div><h3>Conclusion</h3><p>Healthcare providers, particularly those in Acute Medicine and EDs, should consider implementing VTE screening protocols for young adults aged 18–35 presenting to ED with reported N<sub>2</sub>O misuse and neurological problems. A thorough assessment of N<sub>2</sub>O usage patterns is essential, alongside the provision of culturally sensitive health education that addresses the unique needs of marginalised communities. Ongoing research is necessary to elucidate the pathophysiological pathways connecting N<sub>2</sub>O use to VTE incidents, particularly its link to increased homocysteine levels.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"16 ","pages":"Article 100184"},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000269/pdfft?md5=42e5004e29bc328ff7eede285e540ca9&pid=1-s2.0-S2666572724000269-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141847179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信